These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16408696)

  • 1. The antineoplastic efficacy of the prodrug Cloretazine is produced by the synergistic interaction of carbamoylating and alkylating products of its activation.
    Baumann RP; Seow HA; Shyam K; Penketh PG; Sartorelli AC
    Oncol Res; 2005; 15(6):313-25. PubMed ID: 16408696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): II. Role of O6-alkylguanine-DNA alkyltransferase in cytotoxicity.
    Baumann RP; Shyam K; Penketh PG; Remack JS; Brent TP; Sartorelli AC
    Cancer Chemother Pharmacol; 2004 Apr; 53(4):288-95. PubMed ID: 14685775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of O6-alkylguanine-DNA alkyltransferase in the cytotoxic activity of cloretazine.
    Ishiguro K; Shyam K; Penketh PG; Sartorelli AC
    Mol Cancer Ther; 2005 Nov; 4(11):1755-63. PubMed ID: 16275997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): I. Direct inhibition of O6-alkylguanine-DNA alkyltransferase (AGT) by electrophilic species generated by decomposition.
    Penketh PG; Shyam K; Baumann RP; Remack JS; Brent TP; Sartorelli AC
    Cancer Chemother Pharmacol; 2004 Apr; 53(4):279-87. PubMed ID: 14704831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazine.
    Ishiguro K; Seow HA; Penketh PG; Shyam K; Sartorelli AC
    Mol Cancer Ther; 2006 Apr; 5(4):969-76. PubMed ID: 16648568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential inhibition of cellular glutathione reductase activity by isocyanates generated from the antitumor prodrugs Cloretazine and BCNU.
    Rice KP; Penketh PG; Shyam K; Sartorelli AC
    Biochem Pharmacol; 2005 May; 69(10):1463-72. PubMed ID: 15857610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. pH-dependent general base catalyzed activation rather than isocyanate liberation may explain the superior anticancer efficacy of laromustine compared to related 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine prodrugs.
    Penketh PG; Finch RA; Sauro R; Baumann RP; Ratner ES; Shyam K
    Chem Biol Drug Des; 2018 Jan; 91(1):62-74. PubMed ID: 28636806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KS900: A hypoxia-directed, reductively activated methylating antitumor prodrug that selectively ablates O(6)-alkylguanine-DNA alkyltransferase in neoplastic cells.
    Baumann RP; Ishiguro K; Penketh PG; Shyam K; Zhu R; Sartorelli AC
    Biochem Pharmacol; 2011 May; 81(10):1201-10. PubMed ID: 21396917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reductive activation of the prodrug 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine (KS119) selectively occurs in oxygen-deficient cells and overcomes O(6)-alkylguanine-DNA alkyltransferase mediated KS119 tumor cell resistance.
    Baumann RP; Penketh PG; Ishiguro K; Shyam K; Zhu YL; Sartorelli AC
    Biochem Pharmacol; 2010 Jun; 79(11):1553-61. PubMed ID: 20005211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-nitrobenzyloxycarbonyl derivatives of O(6)-benzylguanine as hypoxia-activated prodrug inhibitors of O(6)-alkylguanine-DNA alkyltransferase (AGT), which produces resistance to agents targeting the O-6 position of DNA guanine.
    Zhu R; Liu MC; Luo MZ; Penketh PG; Baumann RP; Shyam K; Sartorelli AC
    J Med Chem; 2011 Nov; 54(21):7720-8. PubMed ID: 21955333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lethality to leukemia cell lines of DNA interstrand cross-links generated by Cloretazine derived alkylating species.
    Penketh PG; Baumann RP; Ishiguro K; Shyam K; Seow HA; Sartorelli AC
    Leuk Res; 2008 Oct; 32(10):1546-53. PubMed ID: 18479747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chloroethylating and methylating dual function antineoplastic agents display superior cytotoxicity against repair proficient tumor cells.
    Zhu R; Baumann RP; Patridge E; Penketh PG; Shyam K; Ishiguro K; Sartorelli AC
    Bioorg Med Chem Lett; 2013 Mar; 23(6):1853-9. PubMed ID: 23395657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection of CHO cells by mutant forms of O6-alkylguanine-DNA alkyltransferase from killing by 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) plus O6-benzylguanine or O6-benzyl-8-oxoguanine.
    Loktionova NA; Xu-Welliver M; Crone TM; Kanugula S; Pegg AE
    Biochem Pharmacol; 1999 Jul; 58(2):237-44. PubMed ID: 10423163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of mammalian O6-alkylguanine-DNA alkyltransferase in a cell line sensitive to alkylating agents.
    Dolan ME; Norbeck L; Clyde C; Hora NK; Erickson LC; Pegg AE
    Carcinogenesis; 1989 Sep; 10(9):1613-9. PubMed ID: 2766456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases.
    Cai Y; Wu MH; Xu-Welliver M; Pegg AE; Ludeman SM; Dolan ME
    Cancer Res; 2000 Oct; 60(19):5464-9. PubMed ID: 11034089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative relationship between guanine O(6)-alkyl lesions produced by Onrigin™ and tumor resistance by O(6)-alkylguanine-DNA alkyltransferase.
    Ishiguro K; Zhu YL; Shyam K; Penketh PG; Baumann RP; Sartorelli AC
    Biochem Pharmacol; 2010 Nov; 80(9):1317-25. PubMed ID: 20654586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
    Giles F; Verstovsek S; Thomas D; Gerson S; Cortes J; Faderl S; Ferrajoli A; Ravandi F; Kornblau S; Garcia-Manero G; Jabbour E; O'Brien S; Karsten V; Cahill A; Yee K; Albitar M; Sznol M; Kantarjian H
    Clin Cancer Res; 2005 Nov; 11(21):7817-24. PubMed ID: 16278404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.
    Liu L; Schwartz S; Davis BM; Gerson SL
    Cancer Res; 2002 Jun; 62(11):3070-6. PubMed ID: 12036916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbamoylating activity associated with the activation of the antitumor agent laromustine inhibits angiogenesis by inducing ASK1-dependent endothelial cell death.
    Ji W; Yang M; Praggastis A; Li Y; Zhou HJ; He Y; Ghazvinian R; Cincotta DJ; Rice KP; Min W
    PLoS One; 2014; 9(7):e103224. PubMed ID: 25068797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of human DNA polymerase beta activity by the anticancer prodrug Cloretazine.
    Frederick AM; Davis ML; Rice KP
    Biochem Biophys Res Commun; 2009 Jan; 378(3):419-23. PubMed ID: 19026985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.